NCT07951281
Performance of Lumetry for Arterial Carbon Dioxide (paCO2) Assessment and Chronic Obstructive Pulmonary Disease (COPD) Screening
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (3)
Arms and interventions
Adults with chronic obstructive pulmonary disease (COPD), stratified by severity (50 GOLD I/II, 50 GOLD III, 50 GOLD IV), and 150 adults without known lung function pathologies. All participants perform a single 60-second lumetry measurement of normal resting breathing, followed by forced spirometry. Participants with COPD additionally undergo arterialized capillary blood gas analysis, with a subgroup of 50 participants with COPD (GOLD III and IV) additionally undergoing transcutaneous carbon dioxide monitoring.
Devices: lumetry
Diagnostic tests: Arterialized Capillary Blood Gas Analysis, Transcutaneous Carbon Dioxide Monitoring, Forced Spirometry
Sites
1 site in 1 country
- Klinik Floridsdorf, Department of Respiratory and Critical Care MedicineVienna, State of Vienna, Austria